These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 8319519

  • 1. Short term pirenzepine treatment is ineffective in suppressing 24-h growth hormone secretion in type 1 diabetes mellitus.
    Krassowski J, Szulc P, Makowska A, Godziejewska M, Jeske W, Zgliczynski S.
    Diabetes Res Clin Pract; 1993 Mar; 19(3):211-6. PubMed ID: 8319519
    [Abstract] [Full Text] [Related]

  • 2. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 3. [Inhibition of growth hormone (GH) response to GHRH in diabetes mellitus type 1 after blockade of the cholinergic system with pirenzepine].
    Krassowski J, Rogala H, Jeske W, Zgliczyński S.
    Pol Arch Med Wewn; 1992 Jul; 88(1):25-9. PubMed ID: 1454656
    [Abstract] [Full Text] [Related]

  • 4. Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: further evidence supporting somatostatin's involvement in GH suppression.
    Goñi MJ, Monreal M, Goñi F, Sopena M, Gil MJ, Moncada E, Salvador J.
    Metabolism; 1997 Nov; 46(11):1305-11. PubMed ID: 9361690
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE, Marazzi N, Cella SG, Cattaneo L, Müller EE.
    J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
    [Abstract] [Full Text] [Related]

  • 6. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL, Wallace WH, Shalet SM.
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [Abstract] [Full Text] [Related]

  • 7. Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus.
    Martina V, Maccario M, Tagliabue M, Corno M, Camanni F.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):392-6. PubMed ID: 2918051
    [Abstract] [Full Text] [Related]

  • 8. Modulation of glucose and growth hormone responses to meals and exercise in type 1 diabetes by cholinergic muscarinic blockade.
    Ara J, Kang S, Creagh FM, Scanlon MF, Peters JR.
    Diabet Med; 1994 Feb; 11(1):92-7. PubMed ID: 8181260
    [Abstract] [Full Text] [Related]

  • 9. Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects.
    Coiro V, Passeri M, Gardini E, Capretti L, Speroni G, Davoli C, Maffei ML, Fagnoni F, Bianconi L, Volpi R.
    Metabolism; 1990 Jul; 39(7):668-75. PubMed ID: 2114512
    [Abstract] [Full Text] [Related]

  • 10. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia.
    Pal BR, Matthews DR, Edge JA, Mullis PE, Hindmarsh PC, Dunger DB.
    Clin Endocrinol (Oxf); 1993 Jan; 38(1):93-100. PubMed ID: 8435890
    [Abstract] [Full Text] [Related]

  • 11. The effect of pirenzepine on growth hormone and blood glucose levels in type I diabetes mellitus. A controlled study in patients on basal bolus insulin treatment.
    Pietschmann P, Schernthaner G.
    Acta Endocrinol (Copenh); 1988 Mar; 117(3):315-9. PubMed ID: 3289300
    [Abstract] [Full Text] [Related]

  • 12. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [Abstract] [Full Text] [Related]

  • 13. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [Abstract] [Full Text] [Related]

  • 14. Reduced growth hormone secretion improves insulin sensitivity in adolescent girls with type 1 diabetes.
    Aman J, Kroon M, Karlsson I, Jones I, Hagenäs L.
    Acta Paediatr; 1996 Jan; 85(1):31-7. PubMed ID: 8834976
    [Abstract] [Full Text] [Related]

  • 15. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.
    Massara F, Ghigo E, Demislis K, Tangolo D, Mazza E, Locatelli V, Müller EE, Molinatti GM, Camanni F.
    Neuroendocrinology; 1986 Jan; 43(6):670-5. PubMed ID: 3093909
    [Abstract] [Full Text] [Related]

  • 16. Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Martina V, Pontiroli AE, Tagliabue M, Calderara A, Maccario M, Pacchioni M, Bertaina S, Bruno G, Pozza G, Camanni F.
    Horm Metab Res; 1994 Mar; 26(3):148-51. PubMed ID: 8005563
    [Abstract] [Full Text] [Related]

  • 17. Cholinergic muscarinic receptor blockade suppresses arginine- and exercise-induced growth hormone secretion in type I diabetic subjects.
    Arends J, Wagner ML, Willms BL.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):389-94. PubMed ID: 3339112
    [Abstract] [Full Text] [Related]

  • 18. Effects of cholinergic modulation on serum insulin-like growth factor-I and its binding proteins in normal and diabetic subjects.
    Ismail IS, Miell JP, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):147-52. PubMed ID: 7535669
    [Abstract] [Full Text] [Related]

  • 19. Galanin abolishes the inhibitory effect of cholinergic blockade on growth hormone-releasing hormone-induced secretion of growth hormone in man.
    Chatterjee VK, Ball JA, Proby C, Burrin JM, Bloom SR.
    J Endocrinol; 1988 Feb; 116(2):R1-2. PubMed ID: 2450944
    [Abstract] [Full Text] [Related]

  • 20. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in young patients with insulin-dependent diabetes mellitus.
    Page MD, Koppeschaar HP, Dieguez C, Gibbs JT, Hall R, Peters JR, Scanlon MF.
    Clin Endocrinol (Oxf); 1987 Mar; 26(3):355-9. PubMed ID: 3652479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.